title: Sublingual allergen immunotherapy for respiratory allergies: what is new?
abstract: Sublingual immunotherapy (SLIT) is a disease-modifying treatment for respiratory allergies that has been used for many years in Europe and has also recently been approved for use in North America. Its use is thus likely to increase. There is more evidence available regarding SLIT efficacy and its good safety profile, making it an appealing treatment option. The majority of studies have mostly focused on grass pollens; however, there are now data available regarding efficacy for other allergens. This review will summarize recent findings from SLIT clinical trials for respiratory allergies, including efficacy, safety, post-discontinuation effects and use in different age groups. Grass pollen, tree pollen, house dust mite and ragweed SLIT studies will be evaluated.
authors.affiliation: Section of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, Fulham wing, London SW3 6NP, UK.
authors.forename: Melina
authors.initials: M
authors.lastname: Makatsori
authors.forename: Moises A
authors.initials: MA
authors.lastname: Calderon
mesh_terms: D006801:Humans; D012130:Respiratory Hypersensitivity / Q000517:prevention & control*; D063729:Sublingual Immunotherapy / Q000639:trends*
keywords: allergen immunotherapy; allergic rhinoconjunctivitis; grass pollen; house dust mite; ragweed; sublingual immunotherapy; tree pollen